首页> 外文OA文献 >Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

【2h】

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Edith A Perez; Sara A Hurvitz; Lukas C Amler; Kirsten E Mundt; Vivian Ng; Ellie Guardino; Luca Gianni;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [J] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, Breast Cancer Research . 2014,第3期

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗联合多西他赛疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究
3. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. [J] . Hamberg P, Bos MM, Braun HJ, Clinical breast cancer . 2011,第2期

机译：II期随机研究比较了曲妥珠单抗和多西他赛联合治疗与序贯治疗的曲妥珠单抗联合多西他赛在HER2 +转移性乳腺癌患者一线化疗中的疗效和安全性：HERTAX试验。
4. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. [J] . Inoue K, Nakagami K, Mizutani Breast cancer research and treatment. . 2010,第1期

机译：曲妥珠单抗单药治疗，曲妥珠单抗加多西他赛与曲妥珠单抗加多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗的随机III期试验：JO17360试验组。
5. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [O] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, 2014

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究
8. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅